Human obesity is characterized by defective fat storage and enhanced muscle fatty acid oxidation, and trimetazidine gradually counteracts these abnormalities

Marco Bucci, Ronald Borra, Kjell Nagren, Romina Maggio, Helena Tuunanen, Vesa Oikonen, Silvia Del Ry, Tapio Viljanen, Markku Taittonen, Sara Rigazio, Daniela Giannessi, Riitta Parkkola, Juhani Knuuti, Pirjo Nuutila, Patricia Iozzo*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    32 Citations (Scopus)

    Abstract

    Bucci M, Borra R, Nagren K, Maggio R, Tuunanen H, Oikonen V, Del Ry S, Viljanen T, Taittonen M, Rigazio S, Giannessi D, Parkkola R, Knuuti J, Nuutila P, Iozzo P. Human obesity is characterized by defective fat storage and enhanced muscle fatty acid oxidation, and trimetazidine gradually counteracts these abnormalities. Am J Physiol Endocrinol Metab 301: E105-E112, 2011. First published April 19, 2011; doi: 10.1152/ajpendo.00680.2010.-An impaired ability to store fatty acids (FA) in subcutaneous adipose tissue (SAT) may be implicated in the pathogenesis of obesity-related diseases via overexposure of lean tissues and production of free radicals from FA oxidation (FAO). We studied regional FA metabolism in skeletal muscle and adipose tissue in humans and investigated the long-term effects of the FAO inhibitor trimetazidine on glucose and FA metabolism. Positron emission tomography (PET) and [C-11] palmitate were used to compare FA metabolism in SAT and skeletal muscle between eight obese and eight nonobese subjects (BMI >=/<30 kg/m(2)). A subgroup of nine subjects underwent a 1-mo trimetazidine administration. PET with [C-11] palmitate and [F-18] fluorodeoxyglucose, indirect calorimetry, and MRI before and after this period were performed to characterize glucose and FA metabolism, fat masses, skeletal muscle triglyceride, and creatine contents. Obesity was characterized by a 100% elevation in FAO and a defect in the FA esterification rate constant (P <0.05) in skeletal muscle. FA esterification was reduced by similar to 70% in SAT (P <0.001) in obese vs. control subjects. The degrees of obesity and insulin resistance were both negatively associated with esterification-related parameters and positively with FAO (P <0.05). Trimetazidine increased skeletal muscle FA esterification (P <0.01) and mildly upregulated glucose phosphorylation (P = 0.066). Our data suggest that human obesity is characterized by a defect in tissue FA storage capability, which is accompanied by a (potentially compensatory) elevation in skeletal muscle FAO; trimetazidine diverted FA from oxidative to nonoxidative pathways and provoked an initial activation of glucose metabolism in skeletal muscle.

    Original languageEnglish
    Pages (from-to)E105-E112
    Number of pages8
    JournalAMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    Volume301
    Issue number1
    DOIs
    Publication statusPublished - Jul-2011

    Keywords

    • fatty acid esterification
    • imaging
    • SKELETAL-MUSCLE
    • INSULIN-RESISTANCE
    • ADIPOSE-TISSUE
    • IN-VIVO
    • ISCHEMIC CARDIOMYOPATHY
    • GLUCOSE-UPTAKE
    • METABOLISM
    • MEN
    • KINETICS
    • HEART

    Fingerprint

    Dive into the research topics of 'Human obesity is characterized by defective fat storage and enhanced muscle fatty acid oxidation, and trimetazidine gradually counteracts these abnormalities'. Together they form a unique fingerprint.

    Cite this